Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration

Retina

Volumn 26, Issue 9, 2006, Pages 988-993

  Dhalla, Mandeep S ^a,b   Shah, Gaurav K ^a,b,d   Blinder, Kevin J ^a,b   Ryan Jr , Edwin H ^c   Mittra, Robert A ^c   Tewari, Asheesh ^a,b  

^a BARNES RETINA INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Vitreoretinal Surgery PA   (United States)

^d NONE   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Intravitreal triamcinolone; Monoclonal antibody; Pegaptanib; Photodynamic therapy; Ranibizumab; Subretinal neovascularization; Vascular endothelial derived growth factor; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ENDOPHTHALMITIS; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UVEITIS; VISION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 33845735960     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000247164.70376.91     Document Type: Article

References (26)

1. Van de Moere A, Sandhu SS, Kak R, et al. Effect of posterior juxtascleral acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 2005;112:1896-1903.
2. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-347.
3. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
4. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
5. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-468.
6. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458-465.
7. Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42-48.
8. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-4480.
9. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002;134:566-576.
10. Gragoudas ES, Adamis AP, Cunningham ET et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
11. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
12. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.e5 [Epub February 3, 2006].
13. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-189.
14. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-1345.
15. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-560.
16. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315.
17. Hashimoto I, Nakanishi H, Shono Y, et al. Angiostatic effects of corticosteroid on wound healing of the rabbit ear. J Med Invest 2002;49:61-66.
18. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005;25:685-690.
19. Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006;90:337-341.
20. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
21. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-468.
22. Bucher RS, Hall E, Reed DM, et al. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch Ophthalmol 2005;123:649-653.
23. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141:149-156.
24. Miller JW. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Presented at: American Society of Retina Specialists Annual Meeting; July 2005; Montreal, Quebec, Canada.
25. Bergers G, Song SN, Meyer-Morse E, Bergsland D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 2003;111:1287-1295.
26. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 2004;18:338-340.